KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P0
Near historical low
vs 5Y Ago
-1.1x
Contraction
Streak
3 yr
Consecutive declineDecelerating
PeriodValue
2025-16.78%
20247.34%
202314.41%
202269.95%
20212.72%
202014.77%
201992.03%
201843.98%
2017-13.61%
201676.96%